Strive, Inc. (ASST), formerly Asset Entities Inc., completed a reverse merger in September 2025 and repositioned itself as a publicly traded Bitcoin treasury company. Its core strategic objective is to increase Bitcoin holdings per common share, using Bitcoin itself as the benchmark against which capital deployment is measured. This model places Strive among a small but growing group of corporate Bitcoin accumulators, though its approach differs in an important respect: rather than relying primarily on convertible debt, Strive has favored perpetual preferred equity to fund purchases.
The company also operates an asset-management arm, Strive Asset Management, an SEC-registered investment adviser that manages more than $2 billion in assets under management (AUM) across exchange-traded funds (ETFs) and related strategies. In January 2026, Strive added a health-technology segment through its merger with medical-device maker Semler Scientific, providing optionality for operational restructuring. This combination of a Bitcoin treasury, an asset-management business, and a smaller healthcare line gives the company a diversified, if still crypto-centric, revenue and asset base.
Over the medium term, competitive positioning will depend on Strive's ability to accumulate Bitcoin without excessive shareholder dilution, sustain its preferred-stock financing on favorable terms, and convert its asset-management franchise into a steadier fee stream. Its debt-free senior capital structure is a differentiator, but the perpetual preferred coupons represent a meaningful structural cost that peers using convertible notes do not face in the same way. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Several forward-looking developments could shape investor sentiment. First, the pace and funding terms of future Bitcoin purchases remain the single most important catalyst, with management signaling ambitions to rank among the largest public corporate Bitcoin holders. Second, continued issuance of perpetual preferred securities, including a fixed-rate offering expected to close in late October 2026, will be closely watched for demand and pricing, since these instruments carry annual coupons in the mid-teens percentage range.
Upcoming earnings releases will also matter, though the operating business is modest relative to the treasury. Consensus revenue projections for 2026 are roughly $11.9 million, with narrower losses expected in 2027 as the business scales. Analyst rating activity has turned more optimistic: firms including Maxim Group, TD Cowen, and B. Riley have raised targets in recent months, and the stock carries a consensus "Strong Buy" rating among analysts polled by S&P Global, with an average one-year price target near the mid-$30s and individual estimates ranging from the low $30s to the mid-$40s.
Regulatory clarity on digital assets and the treatment of corporate Bitcoin holdings is another potential catalyst, as is any further M&A activity aimed at adding treasury assets or operational businesses.
Strive's trajectory is disproportionately influenced by Bitcoin's price, which itself responds to liquidity conditions, inflation expectations, and institutional adoption trends such as spot Bitcoin ETF inflows. Higher interest rates raise the company's cost of preferred-stock financing and can pressure risk assets broadly, while lower rates and abundant liquidity tend to support both Bitcoin and capital-raising activity.
The regulatory climate is a pivotal swing factor. Clearer rules for digital-asset custody, accounting, and taxation could broaden institutional participation and reinforce corporate treasury adoption, whereas restrictive policy could curb it. Geopolitical developments that drive demand for decentralized assets may also feed into sentiment. Because a large share of Strive's value is tied to a volatile commodity-like asset, macroeconomic shifts transmit quickly into both its balance-sheet value and its stock price.
Looking into 2026 and beyond, Strive's long-term story rests on a few structural themes. The first is execution of its "Bitcoin per share" framework: whether the company can grow per-share holdings faster than dilution from equity and warrant conversions. The second is the sustainability of its preferred-stock financing, where perpetual coupons in the mid-teens percentage range must ultimately be supported by treasury appreciation or operating cash flow.
Cost-structure evolution and margin durability in the asset-management and healthcare segments will be secondary but relevant factors, as they determine whether the operating business can move toward breakeven and reduce reliance on external capital. Competitive threats are rising as more companies adopt Bitcoin treasury models, which could increase competition for capital and compress the relative scarcity premium attached to the strategy.
Capital-allocation priorities, including any share repurchases, additional preferred issuance, or strategic acquisitions, will shape how much of the treasury's value accrues to common shareholders after accounting for preferred claims. While analyst expectations have become more constructive, with price targets generally revised upward, the wide dispersion in those targets reflects genuine uncertainty about Bitcoin prices and financing costs. The 2026 outlook therefore depends less on a single forecast and more on the interaction of crypto markets, capital access, and disciplined execution. From what I see, this remains an area worth monitoring closely.
In my own analysis, I regularly turn to Tickeron’s AI Trend Prediction Engine to help evaluate potential price direction for holdings like this one. The tool offers data-driven forecasts and trend signals that complement fundamental research, giving a clearer picture of short-term momentum alongside longer-term themes. It has become a practical addition to my routine when assessing volatility around crypto-exposed names.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Expect a price pull-back in the near future.
The Moving Average Convergence Divergence Histogram (MACD) for ASST turned negative on September 22, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 24 similar instances when the indicator turned negative. In 24 of the 24 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ASST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ASST's RSI Oscillator exited the oversold zone, 22 of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on ASST as a result. In 57 of 63 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.
Following a +20.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where ASST advanced for three days, in 140 of 161 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
ASST may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 61 of 78 cases where ASST Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. ASST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.378) is normal, around the industry mean (2.409). P/E Ratio (-39.088) is within average values for comparable stocks, (-3.173). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.319). Dividend Yield (0.000) settles around the average of (0.271) among similar stocks. ASST's P/S Ratio (113.636) is very high in comparison to the industry average of (15.798).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ASST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry InvestmentManagers